NDAINTRAVENOUSPOWDER
Approved
Jul 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
MEROPENEM (meropenem) by R-Pharm US is [ see microbiology () ]. Approved for acute pyelonephritis, complicated urinary tract infection, hospital-acquired pneumonia and 2 more indications. First approved in 2023.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Meropenem is a broad-spectrum intravenous carbapenem antibiotic indicated for serious gram-negative and gram-positive bacterial infections including sepsis, meningitis, hospital-acquired pneumonia, and complicated intra-abdominal infections. It works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins. The product treats nosocomial and community-acquired severe infections across multiple organ systems.
$3MPart D
GrowthEarly-stage growth product with low Part D penetration suggests significant commercial upside and expansion opportunities for field and marketing teams.
Mechanism of Action
[ see Microbiology () ].
Worked on MEROPENEM at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.